EWING, N.J., April 05, 2018 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ:ATRS) (the Company) today announced that the U.S. Food and Drug Administration (FDA or the Agency) acknowledged receipt of the Company’s March 29, 2018 resubmission to…Original Article
You may also like
Scientists Race to Test Treatments as Ebola Outbreak...
The New Race to Find Treatments for Measles
Medical Advances Are Keeping a Health Reporter Busy
As Ebola Spreads, Scientists Race to Find Vaccines and...
Shortage of Chemotherapy Drugs Brings Rationing Fears...
A Loophole Brings Cystic Fibrosis Patients a...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
